Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2013
Investor Conference Call to Be Held Thursday, August 1, 2013 at 8:30 am EDT
NEW YORK, July 30, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc.
(Nasdaq:KERX), a biopharmaceutical company focused on the acquisition,
development and commercialization of medically important pharmaceutical
products for the treatment of renal disease, today announced that a conference
call will be held on Thursday, August 1, 2013 at 8:30 a.m. EDT to discuss
results for the second quarter ended June 30, 2013 and a business outlook for
the remainder of 2013. Ron Bentsur, Chief Executive Officer of Keryx, will
host the call.
In order to participate in the conference call, please call 1-877-869-3847
(U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio
recording of the conference call will be available for replay at
http://www.keryx.com, for a period of 15 days after the call.
Keryx will announce its financial results for this period in a press release
to be issued prior to the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an
oral, ferric iron-based compound that has the capacity to bind to phosphate
and form non-absorbable complexes. Keryx has completed a U.S.-based Phase 3
clinical program for Zerenex for the treatment of hyperphosphatemia (elevated
phosphate levels) in patients with end-stage renal disease on dialysis,
conducted pursuant to a Special Protocol Assessment (SPA) agreement with the
Food and Drug Administration (FDA), and the New Drug Application filing with
the FDA and the Marketing Authorization Application filing with the European
Medicines Agency (EMA) are pending submission. Zerenex is also in Phase 2
development in the U.S. for the management of phosphorus and iron deficiency
in anemic patients with Stages 3 to 5 non-dialysis dependent chronic kidney
disease. In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii
Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing
approval of ferric citrate in Japan for the treatment of hyperphosphatemia in
patients with chronic kidney disease. Keryx is headquartered in New York City.
CONTACT: Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.